Nuon Therapeutics Inc. Completes Licensing, Supply and Collaboration Agreement on Tranilast With Kissei Pharmaceutical Co., Ltd.
7/23/2007 11:14:19 AM
SAN FRANCISCO--(BUSINESS WIRE)--Nuon Therapeutics, Inc., a clinical stage biotechnology company, today announced the completion of a licensing, supply and collaboration agreement on tranilast with Kissei Pharmaceutical Co., Ltd., Matsumoto City, Japan.
The agreement will enable Nuon Therapeutics to advance tranilast, the company’s lead compound, through the next phase of clinical development while giving Kissei the exclusive option right for research, development and marketing of tranilast in Japan and Korea for the field of autoimmune diseases, including multiple sclerosis (MS). The terms include provisions for Kissei to supply tranilast to Nuon Therapeutics for clinical trials and license Nuon related intellectual property on tranilast. The agreement also establishes a collaborative relationship between Nuon Therapeutics and Kissei for the development of additional portfolio products.